1University of Colorado Cancer Center.
2University of Michigan Rogel Cancer Center.
J Natl Compr Canc Netw. 2021 Jan 6;19(1):16-27. doi: 10.6004/jnccn.2021.0002.
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
NCCN 急性髓系白血病（AML）指南为基于临床试验的 AML 成人诊断和治疗提供了建议，这些临床试验显著改善了治疗效果，或者提供了有关预后因素的新信息，旨在帮助医生做出临床决策。这些 NCCN 指南见解侧重于 NCCN 指南的最近一些精选更新，包括 AML 中的家族遗传改变、低危急性早幼粒细胞白血病或有利风险 AML 中的诱导后或缓解后治疗策略、围绕 venetoclax 为基础的治疗使用的原则，以及不希望在治疗期间接受输血的患者的注意事项。
